CANSEARCH Research Platform in Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, University of Geneva, Geneva, Switzerland.
Division of Pediatric Oncology and Hematology, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Pharmacogenomics J. 2022 Feb;22(1):9-18. doi: 10.1038/s41397-021-00251-7. Epub 2021 Oct 28.
Acute Graft versus Host Disease (aGvHD) grades 2-4 occurs in 15-60% of pediatric patients undergoing allogeneic haematopoietic stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by conditioning regimens administered prior to allo-HSCT serve as an initial trigger for aGvHD. DNA-repair mechanisms may play an important role in mitigating this initial damage, and so the variants in corresponding DNA-repair protein-coding genes via affecting their quantity and/or function. We explored 51 variants within 17 DNA-repair genes for their association with aGvHD grades 2-4 in 60 pediatric patients. The cumulative incidence of aGvHD 2-4 was 12% (n = 7) in the exploratory cohort. MGMT rs10764881 (G>A) and EXO rs9350 (c.2270C>T) variants were associated with aGvHD 2-4 [Odds ratios = 14.8 (0 events out of 40 in rs10764881 GG group) and 11.5 (95% CI: 2.3-191.8), respectively, multiple testing corrected p ≤ 0.001]. Upon evaluation in an extended cohort (n = 182) with an incidence of aGvHD 2-4 of 22% (n = 40), only MGMT rs10764881 (G>A) remained significant (adjusted HR = 2.05 [95% CI: 1.06-3.94]; p = 0.03) in the presence of other clinical risk factors. Higher MGMT expression was seen in GG carriers for rs10764881 and was associated with higher IC50 of Busulfan in lymphoblastoid cells. MGMT rs10764881 carrier status could predict aGvHD occurrence in pediatric patients undergoing allo-HSCT.
急性移植物抗宿主病(aGvHD)在接受异基因造血干细胞移植(allo-HSCT)的儿科患者中发生率为 15-60%。allo-HSCT 前预处理方案对正常组织的附带损伤是 aGvHD 的初始触发因素。DNA 修复机制可能在减轻这种初始损伤方面发挥重要作用,因此,相应的 DNA 修复蛋白编码基因突变通过影响其数量和/或功能。我们在 60 名儿科患者中探索了 17 个 DNA 修复基因中的 51 个变体与 2-4 级 aGvHD 的相关性。在探索性队列中,2-4 级 aGvHD 的累积发生率为 12%(n=7)。MGMT rs10764881(G>A)和 EXO rs9350(c.2270C>T)变体与 2-4 级 aGvHD 相关[比值比=14.8(rs10764881 GG 组中 0 例事件)和 11.5(95%CI:2.3-191.8),多重检验校正 p≤0.001]。在一个包含 182 名患者的扩展队列(2-4 级 aGvHD 发生率为 22%,n=40)中进行评估时,只有 MGMT rs10764881(G>A)在存在其他临床危险因素的情况下仍然显著(调整后的 HR=2.05[95%CI:1.06-3.94];p=0.03)。rs10764881 的 GG 携带者中观察到较高的 MGMT 表达,并与淋巴母细胞中更高的 Busulfan IC50 相关。MGMT rs10764881 携带者状态可预测接受 allo-HSCT 的儿科患者发生 aGvHD。